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1. Introduction 
Pancreatic cancer is the fourth leading cause of cancer death in the U.S. According to the 
Surveillance Epidemiology and End Results (SEER) program, the median age at diagnosis 
between 2003-2007 was 72 years of age, and the incidence of new cases diagnosed during 
this period in all races was 13.3 per 100,000 men and 10.5 per 100,000 women. The median 
age at death for pancreatic cancer during the same period was 73 years of age, and the 
mortality rate for all races was 12.3 per 100,000 men and 9.4 per 100,000 women.  
Pancreatic cancer has a 22.5% 5-year survival rate when localized to the pancreas at 
diagnosis, and it decreases to 1.9% when metastasized. The lifetime risk to develop 
pancreatic cancer is 1.41%, and it is the same for men and women. (National Cancer 
Institute, 2011) Different types of pancreatic cancers originate from different type of 
pancreatic cells. About 95% of pancreatic cancers originate from exocrine cells. Of these, 
the most common is pancreatic adenocarcinoma (about 95%). Other less common types of 
exocrine tumors are: adenosquamous carcinomas, squamous cell carcinomas, giant cell 
carcinomas, intraductal papillary mucinous neoplasms (IPMN), mucinous 
cystadenocarcinoma, pancreatoblastoma, cystadenocarcinoma and pseudopapillary 
tumors. About 5% of pancreatic cancers originate from endocrine cells, and are known as 
pancreatic neuroendocrine tumors (NETs). Each of these tumors is named according to 
the hormone they produce: insulinomas, glucagonomas, gastrinomas, somatostatinomas, 
VIPomas. (American Cancer Society, 2011) Cystic pancreatic lesions are common and have 
a wide range of malignant potential. These lesions include, but are not limited to, serous 
cystadenomas (low potential for malignancy), mucinous cystic neoplasms, and IPMN. 
Based on the degree of dysplasia, these neoplasms are classified into benign 
(adenomatous), low-grade malignant (borderline) and malignant (carcinoma in situ and 
invasive cancer). (Brugge et al, 2004) 
Pancreatic cancer must be managed with a multidisciplinary approach. Endoscopy has a 
primary role in the diagnosis and staging of pancreatic cancer. Endoscopic ultrasound 
(EUS) is the most frequently used modality for this purpose. Treatment with curative 
intention involves surgery, with adjuvant therapy (chemotherapy and/ or radiation) in 
some cases. Most cases are diagnosed when curative resection is not possible. Technologic 
developments have introduced new endoscopic approaches to the palliation of these 
advanced cases.  
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This chapter will cover the endoscopic technology currently available for diagnosis, staging 
and palliation of pancreatic cancer. Promising interventional techniques for the diagnosis 
and palliation of this neoplasia are currently under development and improvement and will 
also be discussed here.  
2. Diagnosis and staging 
The imaging modalities involved in the diagnosis and staging of pancreatic cancer include 
Computed Tomography (CT), Magnetic Resonance Imaging (MRI), EUS and Endoscopic 
Retrograde Cholangiopancreatography (ERCP). Only the endoscopic modalities, EUS and 
ERCP, will be reviewed here. 
 
Fig. 1. 55 year-old male with a pancreatic mass found in abdominal CT during work up of 
abdominal pain and weight loss. EUS revealed a 2.5cm mass located at the neck of the 
pancreas. 
EUS is a combination of endoscopy and intraluminal ultrasound that allows the 
introduction of high frequency ultrasound waves in the gastrointestinal tract to visualize the 
wall and adjacent structures. It is considered the procedure of choice for the diagnosis and 
staging of pancreatic cancer. High resolution endosonographic images can be obtained due 
to the short distance between the probe and the target lesion. It has become an accepted 
modality for the diagnosis of pancreato-biliary diseases. (Yamao et al, 2009) EUS has great 
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utility in the diagnosis of pancreatic cancer and other gastrointestinal malignancies, as it 
allows the etiological diagnosis by tissue acquisition by fine needle aspiration (FNA).  
EUS is contraindicated in those circumstances where the lesion cannot be clearly visualized, 
presence of an interposed vessel in the path between the needle and the target lesion, 
bleeding diathesis and risk of tumor seeding. (Yamao et al, 2009) 
 
Fig. 2. FNA of a lymph node found during diagnostic EUS in 59 year-old male with 
metastatic pancreatic adenocarcinoma.  
Radial and curve linear array echoendoscopes are available for EUS. Radial echoendoscopes 
provide a circumferential view at right angle to the shaft of the scope, similar to those 
provided by CT. The linear array echoendoscope generates longitudinal sector images 
parallel to the axis of the endoscope giving a 120° to 180° scanning view. The linear 
echoendoscope also has an instrument channel that ranges in size (2.0 to 3.8mm) and allows 
not only histological biopsies to be taken by FNA, but also therapeutic interventions that 
will be discussed later in this chapter. (Yamao et al, 2009; Hawes & Fockens, 2006) EUS-FNA 
needles can be locked in a fixed position on the echoendoscope and advanced into the lesion 
by the endoscopist under ultrasonographic guidance. Needle sizes available are 19, 22 and 
25 gauge, and allow for a depth of penetration of up to 10cm. A 19 gauge trucut needle is 
also commercially available and allows for the specimens to be processed for 
immunohistochemical and gene analysis. (Yamao et al, 2009) The 25 gauge needle has the 
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advantage of being more flexible and passes through the tissue more easily, however is less 
echogenic and can be more difficult to visualize during FNA. In the other hand, the stiffness 
of the 22 gauge needle produces less distortion and probably allows for firmer pressure to 
be applied. (Hawes, 2010a) 
 
Fig. 3. 55 year-old male with pancreatic neck mass. EUS-FNA was performed and cytology 
was consistent with adenocarcinoma.  
Prior to the development of EUS-FNA, pancreatic FNA or core biopsy were performed 
either during surgery or percutaneously under US or CT guidance. Intra-operative sampling 
considerably increases the operating time, and the percutaneous approach has reported 
sensitivity of about 80%, but at the expense of possible needle-track seeding. (Bret et al, 1986; 
Ferrucci et al, 1979; Smith et al, 1980; Caturelli et al, 1985) EUS-FNA is associated with high 
rates of adequate tissue sampling and diagnostic accuracy. A prospective study in 457 
patients undergoing EUS-FNA in 554 lesions revealed a sensitivity, specificity, and accuracy 
of 92%, 93%, and 92% for lymph nodes, 88%, 95%, and 90% for extraluminal masses, and 
61%, 79% and 67% for gastrointestinal wall lesions, respectively. (Wiersema et al, 1997) 
DeWitt summarized the reports of multiple authors on FNA of pancreatic tumors and 
reported the accuracy, sensitivity and specificity to be 88%, 85% and 98%, respectively in 
among nearly 1700 patients (DeWitt, 2006, as cited in Hawes & Fockens, 2006). Summarizing 
the results of 23 studies including 1,096 patients over a 21-year period, the sensitivity of EUS 
for the detection of a pancreatic mass was in the range of 85-100%. (Al-Haddad & Eloubeidi, 
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2010; Yasuda et al, 1988; DeWitt et al, 2004; Chhieng et al, 2002; Eloubeidi & Tamhane, 2005) 
The operating characteristics of EUS-FNA of solid pancreatic masses in 547 patients were: 
sensitivity 95%, specificity 92%, positive predictive value 98% and negative predictive value 
80%, with and overall accuracy of 94.1%. (Eloubeidi et al, 2007) Such accuracy numbers 
allow for preoperative counseling of patients, minimizing surgeon’s operative time in cases 
of unresectable disease, and avoiding surgical biopsies in those with inoperable disease, also 
allowing for conservative management of patients with benign pathology results. (Eloubeidi 
et al, 2007) 
To compare the diagnostic yield and complication rates of 22 gauge and 25 gauge needles 
during EUS-FNA of solid pancreatic masses, a group prospectively randomized 131 patients 
with suspected pancreatic lesions. (Siddiqui et al, 2009) EUS-FNA with 22 gauge needle was 
performed in 64 patients and 25 gauge needle was used in 67 patients. Overall, cytology was 
diagnostic in 120 of 131 patients (91.6%): 87.5% with 22 gauge and 95.5% with 25 gauge. The 
difference was not statistically different (p=0.18) but there was a trend toward a higher 
accuracy with the 25 gauge. A similar number of passes was performed in both groups and 
no complications were reported in either arm. 
The 19 gauge Trucut biopsy needle contains an 18mm long specimen tray that acquires 
larger tissue samples while preserving tissue architecture to allow histologic examination. 
(Levy, 2007) It was introduced in 2002 and overcomes certain limitations of the FNA needle: 
certain tumors (stromal tumors, lymphomas and well-differentiated pancreatic tumors) are 
difficult to diagnose based on cytology alone and the diagnosis accuracy relies on 
immediate review of the specimen for sampling adequacy by an on-site cytopathologist. 
When used in conjunction with an echoendoscope, these large caliber needles procure larger 
specimens for histopathological analysis by means of EUS trucut needle biopsy (EUS-TNB). 
(Varadarajulu et al 2004) A tissue core sample has several advantages: better distinction 
between well-differentiated adenocarcinoma and chronic pancreatitis, which accounts for 
both false-positive and false-negative FNA results; appropriate cellular sub-typing and 
architectural analysis in the diagnosis of lymphoma, as well as use of special stains, all of 
which are of limited usefulness with FNA specimens; and elimination of the need for a 
cytopathologist to assess specimen adequacy, thereby reducing duration and cost of the 
procedure. (Larghi et al, 2004) A pilot study for the 19 gauge Trucut needle included 18 
patients undergoing EUS-FNA and EUS-TNB of different lesions (11 mediastinal masses, 3 
pancreatic masses, 3 gastric tumor/ cyst/ lymphoma, and 1 adrenal mass). There was no 
significant difference in the adequacy of the specimens for evaluation (83% vs. 100% 
adequate specimens in EUS-TNB and EUS-FNA respectively), or in the diagnostic accuracy 
of EUS-TNB from EUS-FNA (78% vs. 89% respectively). Two complications were 
encountered: one patient required surgery for mediastinitis and another patient was 
managed conservatively for immediate bleeding. (Varadarajulu et al 2004) A group in 
London prospectively evaluated the safety and accuracy of EUS-FNA alone vs. combined 
EUS-FNA and EUS-TNB (EUS-FNA/TNB). (Wittmann et al 2006) A total of 159 patients 
underwent EUS-FNA alone (lesions < 2cm) or the combination of both modalities (lesions of 
2cm or more). Adequate samples were obtained in 91%, 88% and 97% by EUS-FNA, EUS-
TNB and EUS-FNA/TNB respectively. From the pancreas (n = 83), adequate samples were 
obtained by FNA in 94% and by TNB in 81%, compared with 87% and 92% from non-
pancreatic sites (n = 76) respectively. Overall accuracy for EUS-FNA alone was 77%, for 
www.intechopen.com
 Pancreatic Cancer – Clinical Management 
 
218 
EUS-TNB alone 73% and for EUS-FNA/TNB 91% (p = 0.008). For pancreatic sampling, the 
accuracy of FNA alone was 77%, for TNB alone was 56% and for FNA/TNB 83%. For non-
pancreatic sampling, the accuracy for EUS-FNA alone was 78%, for EUS-TNB alone 83% and 
for EUS-FNA/TNB 95% (p = 0.006). The complication rate was 0.6% (one patient with 
moderate self-limited abdominal pain and another patient with bile leak requiring 
endoscopic stent replacement). Another group prospectively enrolled 247 patients to 
determine factors predicting a positive diagnostic yield and the safety of EUS-TBN. (Thomas 
et al, 2009) The lesions sampled were in the pancreas (113), esophagogastric wall (34), and 
extrapancreatic areas (100; 52 of those were lymph nodes). The overall accuracy was 75%. 
The overall complication rate was 2% (bronchopneumonia, minor hemoptysis, minor 
hematemesis, mucosal tear, retropharyngeal abscess) with no procedure-related deaths. A 
higher diagnostic yield was found when the lesion was approached through the stomach 
and when more than two passes were made. With the aim of comparing EUS-FNA using 25 
gauge and 22 gauge needles with the EUS guided 19 gauge Trucut needle in solid pancreatic 
mass, a group in Japan prospectively enrolled 24 patients. (Sakamoto et al, 2009) The 25 
gauge EUS-FNA was technically easier and obtained superior overall diagnostic accuracy, 
especially in lesions of the pancreas head and uncinate process. Overall accuracy for the 25 
gauge, 22 gauge and Trucut needle was 91.7%, 79.7% and 54.1%, respectively. Accuracy for 
cytological diagnosis irrespective the site of lesions with 25 gauge, 22 gauge and Trucut 
needles was 91.7%, 75% and 45.8%, respectively. For uncinate masses, it was 100%, 33.3%, 
and 0% respectively. 
Most endosonographers consider EUS-FNA the procedure of choice for sampling of 
pancreatic masses, however, EUS-TNB has a role in selected settings. The most clear 
advantage of EUS-TNB over EUS-FNA is in the diagnosis of disorders for which histology is 
necessary and cytology is inadequate, such as autoimmune pancreatitis and chronic 
‘nonspecific’ pancreatitis. For other pancreatic disorders including cystic pancreatic tumors, 
islet cell tumors, secondary metastatic solid pancreatic tumor, and primary solid pancreatic 
tumors, EUS-TNB and EUS-FNA have often complementary roles. (Levy, 2007) 
Pancreatic masses found in the background of chronic pancreatitis present a particular 
challenge to endoscopists. Better methods to detect pancreatic tumors in this setting and to 
better target the fine needle aspiration within a pancreatic mass to optimize sampling are 
needed. The development of image enhancing techniques and/or the use of contrast agents 
may fulfill these needs. Elastography is a method for real-time evaluation of tissue stiffness. 
Elastography uses a hue color map (red-green-blue) to display tissue stiffness: hard or stiff 
tissue is shown in dark blue, medium hard tissue areas in cyan, intermediate hardness tissue 
areas in green, medium soft tissue areas in yellow and soft tissue in red. (Hawes, 2010) A 
group from Spain reported the use of EUS elastography for the characterization of solid 
pancreatic masses in 130 patients and compared them with 20 normal controls. Four 
elastographic patterns were described, with high concordance among the 2 blinded 
investigators. A green-predominant pattern (homogeneous or not) excluded malignancy 
with high accuracy whereas a blue-predominant pattern (homogeneous or heterogeneous) 
supported a malignancy diagnosis. Sensitivity, specificity and overall accuracy for the 
diagnosis of malignancy were 100%, 85.5% and 94% respectively. (Iglesias-Garcia et al, 2009) 
A Japanese group investigated the usefulness of EUS combined with contrast enhancement 
in the preoperative localization of pancreatic endocrine tumors (PET) and the differentiation 
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between malignant and benign PETs. (Ishikawa et al, 2010) This group retrospectively 
studied 62 pathologically confirmed PETs found in 41 patients who had undergone EUS, 
multiphasic multidetector computed tomography (MDCT) and transabdominal ultrasound 
(US). Contrast-enhanced EUS had 95% sensitivity in identifying PETs compared with 80% 
with MDCT and 45% with US. Heterogeneous ultrasonographic texture was the most 
significant factor for malignancy. It was also noted that when contrast was used with EUS, 
PETs showed contrast enhancement except in areas of hemorrhage or necrosis. The optimal 
use of elastography and contrast enhanced EUS would be to define an optimal target area 
within a pancreatic mass to maximize the cytologic yield. (Hawes, 2010) 
Cystic pancreatic lesions are commonly found nowadays given the development and 
availability of different imaging tests that are often performed for unrelated reasons. Cystic 
lesions are sometimes difficult to diagnose. Cross-sectional imaging is often non-diagnostic 
due to the small size of the cystic lesions. EUS has become useful for the diagnosis of these 
lesions as it provides high resolution images and allows the performance of FNA of the 
cystic fluid for cytology and tumor marker determinations. A large, prospective multicenter 
study looking at the imaging, cyst fluid cytology and cyst fluid tumor markers found that  
 
Fig. 4. The picture demonstrates one of the multiple peri-pancreatic lymph nodes found in a 
patient with metastatic pancreatic adenocarcinoma. The largest measured 25mm. FNA of 
the lymph node was performed and cytology was consistent with poorly differentiated 
adenocarcinoma.  
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the cystic fluid CEA (using a cutoff value of 192 ng/ mL) was able to differentiate mucinous 
vs. nonmucinous cystic lesions with an accuracy of 79%, which was significantly higher than 
the accuracy of EUS morphology (51%) or fluid cytology (59%) (p<0.05). (Brugge et al, 
2004b) 
Staging of pancreatic malignancy is done according to the American Joint Committee for 
Cancer (AJCC) Staging TNM classification. This describes the tumor extension (T), lymph 
node (N) and distant metastases (M) of tumors, respectively. Accuracy of the T staging by 
EUS ranges from 63% to 94% and nodal (N) staging ranges from 41% to 86%, (DeWitt et al, 
2004; Palazzo et al, 1993; Gress et al, 1999; Rivadeneira et al, 2003) which is superior to CT 
and trans abdominal ultrasound. (Palazzo et al, 1993; Gress et al, 1999; Rivadeneira et al, 
2003; Agarwal et al, 2004) Comparative studies between EUS and cross-sectional imaging 
have generally shown that EUS is superior for local tumor staging (T and N) in esophageal, 
pancreatic and rectal cancer, but CT is still necessary for full assessment of metastatic 
disease. (Hawes, 2010) EUS, however, can be of value when evaluating for metastases. Part 
of the liver can be visualized by EUS and suspected metastatic lesions can be sampled. 
Celiac lymph nodes can also be biopsied if appearing suspicious and ascites can be aspirated 
and sent for cytology to assess for peritoneal metastases. (Al-Haddad & Eloubeidi, 2010) 
EUS is associated with a low rate of complications. A study in 322 patients and 345 lesions 
revealed an overall complication risk of 1.6%. This study involved pancreatic EUS-FNA in 
248 cases (134 solid lesions and 114 cystic lesions) and complications were observed in 4 
(1.2%) patients with pancreatic cystic lesions (acute pancreatitis in 3, and aspiration 
pneumonia in 1). No complications resulted from FNA of solid pancreatic lesions. (O’Toole 
et al, 2001) Despite the low complication risk, life threatening complications have been 
sporadically reported: fulminant cholangitis after FNA of a liver metastasis and 
uncontrolled bleeding from a pseudoaneurysm after pancreatic FNA, (Erickson, 2004) 
massive bleeding from a gastric GIST (Inoue et al, 2006) and acute portal vein thrombosis 
after FNA of pancreatic cancer. (Matsumoto et al, 2003) A prospective cohort study in 355 
patients evaluated the frequency of major complications following EUS-FNA of solid 
pancreatic masses and found major complications in 2.54% with acute pancreatitis 
developing in 3 patients (0.85%). (Eloubeidi et al, 2006) 
ERCP played a major role in the diagnosis of pancreatic disease since its development in the 
late 1960s. However, the introduction and advances of imaging studies, especially MRCP, 
have shifted the ERCP applications toward therapeutic interventions. ERCP is seldom 
performed for diagnostic purposes, but it provides detailed opacification of the main and 
branch ducts (pancreatogram). The morphologic changes in the ductal system usually 
correlate with histologic changes. This is limited in the case of cysts that do not 
communicate with the pancreatic duct. ERCP also allows collection of pure pancreatic juice 
for cytology and gene analysis, brush cytology, biopsy of the pancreatic duct, and 
introduction of baby scopes or ultrasonic probes into the pancreatic duct for pancreatoscopy 
and intraductal ultrasound (IDUS), respectively. (Fujita et al, 2004)  
Pancreatography can suggest the diagnosis of pancreatic cancer. A Japanese study 
comparing the pancreatographic findings of autoimmune pancreatitis and cancer revealed 
that an obstructed main pancreatic duct and an upstream duct dilation to a diameter greater 
than 4mm were significantly more common in cancer cases; meanwhile, autoimmune 
pancreatitis had a higher prevalence of narrowing of the main pancreatic duct for more than 
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3cm of its length and a higher prevalence for the presence of side branches in the narrowed 
portions if the main pancreatic duct. (Nishino et al, 2010) The pancreatographic features 
suggestive of pancreatic cystic neoplasms include displacement of the pancreatic duct, 
pancreatic duct strictures, and the degree of pancreatic ductal obstruction. In the case of 
IPMN, the main pancreatic duct may be dilated diffusely or in a segment fashion depending 
on the volume of mucus produced, the presence of ductal obstruction and the presence and 
distribution of intraductal tumors. Enlargement of the main pancreatic duct is a frequent 
pancreatographic abnormality in IPMN, present in about 77% of patients; side branch 
ectasia or cystic dilation occurs in about 51% of the cases. (Telford & Carr-Locke, 2002) 
Pancreatic juice and mucus can be aspirated directly from the pancreatic duct during ERCP, 
either by catheter or pancreatoscopy. Stimulation of pancreatic exocrine secretion by 
administration of secretin may improve the diagnostic yield. The samples are sent for 
cytology, as well as analysis of mucin, tumor marker levels, and amplification of molecular 
abnormalities. (Telford & Carr-Locke, 2002) Examination of the pancreatic juice collected 
during cannulation yielded positive results in 52.3% of pancreatic cancer patients. Higher 
positive rates were obtained when washing with saline (63.2%) and aspirating after secretin 
stimulation (51.3%), as well as in cases of pancreatic head cancer (70.6%). (Kameya et al, 
1981) For IPMN, the specificity of the cytology of the pancreatic juice is 100%, and the 
sensitivity is 62.2% when collected by pancreatoscopy and 38.2% when collected by catheter. 
(Chen 2007; Yamaguchi et al, 2005) 
Brush cytology of pancreatic duct strictures or elevated intraductal lesions during ERCP has 
a sensitivity and specificity to detect malignancy of 48-76% and 100%, respectively, and 
accuracy of 70-76.4%. (Telford & Carr-Locke, 2002; Chen 2007; Ferrari et al, 1994; 
Vandervoort et al, 1999; Uchida et al, 2007) Accuracy may be influenced by location of 
sampling within the pancreas, technical errors and interpretation of the sample. (Chen 2007) 
Strictures located at the head and body of the pancreas usually yield high rates of positive 
cytology. The diagnostic yield is overall enhanced by concomitant brushing of pancreatic 
and bile duct strictures. (McGuire et al, 1996) A retrospective study evaluating the 
diagnostic yield of combining EUS-FNA with brushing cytology during the work up of 
pancreatic cancer revealed that the combined use of these two modalities provides a better 
diagnostic yield in pancreatic adenocarcinoma than either one alone. The sensitivity, 
specificity and accuracy were 69.2, 93.8, and 77.3% for EUS-FNA alone, 50.8, 100, and 67% 
for brushing cytology alone, and 84.6, 100, and 89.7% for combination of EUS-FNA with 
brushing cytology. (Jing et al, 2009) A recent study to determine whether KRAS (proto-
oncogene) mutations could be identified in pancreatobiliary stricture brushings and to 
compare the performance characteristics of KRAS mutation analysis to cytology and 
fluorescence in situ hybridization (FISH) for detection of carcinoma revealed that combined 
KRAS mutation and FISH analysis appear to increase the cancer detection rate in patients 
with pancreatobiliary strictures. The KRAS mutation and polysomic FISH (positive) results 
were identified in 69% and 63% pancreatic adenocarcinoma specimens, respectively, with a 
combined sensitivity of 86%. (Kipp et al, 2010) In the case of cysts, a new through the needle 
cytological brush system (Echo-Brush) seeks to solve the poor cellularity typically obtained 
by EUS-FNA. This system consists in the introduction of the brush through a 19 gauge EUS 
needle after aspiration of the cyst fluid. The brush is used to scrub the cystic wall and is 
processed as standard brushing. Studies have had conflicting results. A group from Spain 
found that the brush was superior to the aspirated fluid for detecting diagnostic cells but 
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didn’t reach statistical significance (73% vs. 36%, p=0.08). In terms of mucinous cells, the 
yield of the cytobrush was significantly higher (50% vs. 18%, p=0.016). (Sendino et al, 2010) 
A group from the United Kingdom evaluating the management of cystic pancreatic lesions 
reported a similar cellularity yield between the FNA group and the brushing group (61.9% 
and 55.0%, respectively). Greater proportion of patients with malignant cystic lesions 
diagnosed by EUS sampling were in the brushing group, but this did not reach significance 
(50% in the brushing group vs. 20% in the FNA group, p=0.524). (Thomas et al, 2010) 
Random transpapillary biopsies of the pancreatic duct can be obtained in the presence of a 
stricture or an elevated lesion. The specificity for the detection of malignancy approaches 
100%, but the sensitivity is variable, ranging from 57% to 100%. The accuracy of these 
biopsies increases when performed during pancreatoscopy. (Telford & Carr-Locke, 2002; 
Chen, 2007) 
Pancreatoscopy is the endoscopy of the pancreatic duct, and it is performed using a mother-
baby scope system: a thin endoscope (baby scope) is introduced into the pancreatic duct 
through the working channel of the duodenoscope (mother scope). This technique has some 
limitations for small size pancreatic ducts: the wider the scope diameter, the better the 
quality of images; the tip-bending system, useful for observing the tortuous pancreatic 
ductal lumen, increases the size of the scope; the use of irrigation and suction system is 
needed to achieve a good endoscopic view, but also increases the size of the scope. Given 
these size limitations, the investigation of IPMN is the best indication for the use of 
pancreatoscopy. (Fujita et al, 2004) The insertion of the pancreatoscope is facilitated by the 
frequently enlarged papillary orifice present in IPMN. Pancreatoscopy in this condition 
allows for endoscopic diagnosis in 67% to 83%, (Nguyen et al, 2009) differentiation of a 
filling defect seen in pancreatography as mucus, tumor or stone, identification of malignant 
features, endoscopic biopsy, and determination of disease extent. Clusters of papillary 
projections in IPMN rising <3mm above the ductal surface can represent hyperplasia or 
adenoma with different degrees of dysplasia. In the other hand, adenocarcinoma is typically 
polypoid and protrudes >3mm into the ductal lumen. Diffuse hyperemia or distinct vessels 
may also be observed and are also considered high-risk features. (Telford & Carr-Locke, 
2002) The cancer detection rate by pancreatoscopy-guided sampling has a sensitivity of 
62.5%, specificity 100%, positive predictive value 100%, and negative predictive value 70.7%. 
(Iqbal & Stevens, 2009) Despite the usefulness of this diagnostic tool, pancreatoscopy 
requires expensive, very fragile equipment and two experience endoscopists to operate it. 
Hence, it is not performed often. (Telford & Carr-Locke, 2002) 
IDUS uses a thin caliber (approximately 2mm in diameter) ultrasound probe with high-
frequency ultrasound (12-30 MHz). For pancreatic IDUS, the ultrasonic probe is advanced into 
the pancreatic duct over a guidewire during an ERCP. However, in some situations it is not 
possible for even a thin caliber prove to pass a stenotic site caused by a mass in the pancreatic 
duct. (Fujita et al, 2004) A study comparing the detection rates of different imaging 
technologies in patients with mucin-producing tumors revealed a detection rate of 21% for CT, 
29% for ultrasound, 83% for pancreatoscopy, 86% with EUS, and 100% for IDUS. (Chen, 2007) 
IDUS is useful in assessing the indications for surgery by revealing mural nodules in mucin-
producing tumors, evaluating the feasibility of partial resection of the tumor, locating multiple 
lesions in pancreatic islet-cell cancer, and differentiating benign from malignant cases of 
localized stenosis of the main pancreatic duct. (Furukawa et al, 1997) 
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Cancer detection rate can be improved by techniques that allow better visualization, such as 
narrow-band imaging (NBI) or by developing techniques that image the lesion at 
microscopic level, such as confocal laser microscopy. NBI during pancreatoscopy has been 
shown to provide better visualization of vascular pattern and tumor vessels than 
conventional white light. (Iqbal & Stevens, 2009) Some authors have reported the ability of 
NBI to identify both the surface structure and mucosal vessels as good as, or even better 
than, conventional white light, regardless of benign or malignant etiology. (Itoi et al, 2009) 
The use of a confocal microscope enables subsurface in vivo histological assessment during 
ongoing endoscopy. This technology also requires the application of a flourophore for 
mucosal fluorescence imaging. Endomicroscopic images can be acquired after intravenous 
application of fluorescein, which also makes the blood vessels clearly visible. The use of this 
technology in the investigation of biliary pathologies has escalated since the introduction of 
a flexible probe-based confocal laser endomicroscopy (pCLE) system. Certain hallmarks and 
patterns have been identified to differentiate benign from malignant epithelium. (Meining, 
2009) The experience in pancreatic pathologies is more limited and developing. A group was 
able to use pCLE to detect and further differentiate pancreatic strictures such as IPMN. 
(Meining et al, 2009) The use of this technology may be helpful to clarify location and types 
of IPMN for a targeted surgical resection. Confocal endomicroscopy is being developed 
further and a new miniprobe small enough to be introduced through a 22 gauge puncture 
needle was developed. Feasibility studies to evaluate the ability of this needle-based 
confocal laser endomicroscopy (nCLE) for in vivo histology of various organs, including 
pancreas, have been carried in animal models with good results. (Becker et al, 2010; 
Mennone & Nathanson, 2011) A multicenter trial assessing the use of nCLE in humans is 
currently being carried.  
3. Therapeutic Interventions 
Endoscopy has no role in the treatment of pancreatic cancer, as the only definite treatment is 
surgical resection when the disease is diagnosed in early stages. For advanced cases, 
palliation is indicated and endoscopy plays an important role. The procedures currently 
performed for palliation of pancreatic cancer involve stent placement for the drainage of 
biliary or pancreatic duct obstruction by ERCP or under EUS guidance, celiac plexus 
neurolysis (CPN), injection of anti-tumor agents, and implantation of fiducial markers to 
guide radiation therapy. Other experimental procedures are being developed to evaluate the 
role of EUS in the application of radiofrequency ablation (RFA) and photodynamic therapy 
(PDT). 
ERCP for drainage of biliary obstruction is the most commonly performed endoscopic 
procedure for palliation of pancreatic cancer. Endoscopic treatment of these malignant 
biliary obstructions is often successful in alleviating symptoms such as jaundice and 
pruritus, reducing the incidence of cholangitis, and increasing biliary drainage so that 
hepatically metabolized chemotherapeutic agents can be offered. (Rogart, 2010) The first 
biliary stents available were made of polyethylene (plastic), and had the drawback of 
occlusion with sludge in about 30% of cases, resulting in recurrence of symptoms and 
development of cholangitis. Self-expanding metal stents (SEMS) had previously been used 
for vascular and urethral indications, and were later developed for biliary applications. 
Initial non-comparative studies reported an occlusion rate of SEMS of 10-18%. In 1992, the 
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Fig. 5. 59 year-old male with biliary obstruction secondary to pancreatic head mass 
(adenocarcinoma). An ERCP was performed and a distal common bile duct stricture can be 
appreciated in the left image. The patient had metastatic disease, and a SEMS was placed for 
palliation of jaundice and pruritus. 
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first prospective randomized clinical trial reporting the patency and cost-effectiveness of 
SEMS vs. plastic stents was published: the median patency of the stent was significantly 
prolonged in patients with metal stent compared with those with a polyethylene stent (273 
days vs. 126 days, p=0.006), and the incremental cost-effectiveness analysis showed that 
initial placement of a SEMS results in a 28% decrease of endoscopic procedures. (Davids et 
al, 1992) Since the introduction of biliary SEMS, several groups have concluded that their 
placement represent a cost-saving strategy, as plastic stents are associated with higher risk 
of recurrent biliary obstruction, which translates into additional procedures, 
hospitalizations, etc. (Arguedas et al, 2002; Kaassis et al, 2003; Moss et al, 2006) There was 
initial concern on the possibility of interfering with subsequent pancreaticoduodenectomy 
after biliary metal stent placement in patients with uncertain surgical status or with 
resectable masses, but this has not been well substantiated. There are actually some reports 
on the cost-benefit that these stents offer to these patients, as well as the longer patency rate, 
need for fewer procedures and fewer episodes of cholangitis. (Rogart, 2010; Wasan et al, 
2005; Chen et al, 2005; Boulay et al, 2010) In addition, insertion of SEMS is advised as the 
treatment of biliary SEMS occlusion, as it provides longer patency and survival, decreases 
the number of subsequent procedures by 50% (compared to plastic stents) and is cost-
effective. (Rogart et al, 2008)  
However, technical failure during ERCP is encountered in up to 10% of cases due to various 
factors including duodenal obstruction, anatomical variations, periampullary diverticulum 
and tightness of the stricture. In these cases, percutaneous transhepatic biliary drainage 
(PTBD) and surgical drainage are options available. The technical success rate for PTBD 
placement is 90% if the intrahepatic system is dilated and 70% in a non-dilated system. The 
morbidity is 7% and the mortality is 5%, and it is contraindicated in the presence of ascites 
and coagulopathy. Surgical drainage, although a possibility, is associated with high 
morbidity and mortality rates (66% and 32%, respectively), as the patients in need for this 
procedure are usually very deconditioned. Hence, the drainage of the biliary system using a 
transgastric or transduodenal approach under EUS guidance has been introduced with a 
reported technical success rate of 92%. Once the common bile duct (CBD) is localized from 
the duodenal bulb or the intrahepatic system is visualized from the stomach, the biliary system 
is accessed under EUS guidance and a stent is deployed under fluoroscopic guidance to form a 
choledochoduodenostomy or a hepaticogastrostomy, respectively. The reported technical 
success rate for hepaticogastrostomy is 90-100% and the clinical success rate is 75-100%. The 
complication rate associated with EUS-guided biliary drainage is 19%, with 8% being due to 
focal biliary peritonitis. Other complications include bleeding, pneumoperitoneum, infection 
caused by stent occlusion/migration, and death. (Ramesh & Varadarajulu, 2008; Irisawa et al 
2009) Plastic stents are the most commonly used during this approach; however, 
transduodenal and transgastric placement of self-expandable metal stents (SEMS) for 
palliation of malignant biliary obstruction has been reported and some authors report 
antegrade placement achieving transpapillary or, in case of post-surgical anatomy, 
transanastomotic placement. (Siddiqui et al, 2011; Nguyen et al, 2010; Artifon et al, 2010) 
EUS-guided pancreatic duct drainage can also be accomplished. There are two techniques: 
1) transmural drainage of the main pancreatic duct; and 2) rendezvous approaches for ERCP 
assistance of transpapillary drainage. (Irisawa et al, 2009) The main indication for the 
pancreatic duct drainage is to alleviate pain caused by pancreatic ductal obstruction 
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associated with chronic pancreatitis and other inflammatory processes. For this reason, this 
will not be discussed further in this chapter.  
 
 
Fig. 6. 40 year-old female with locally advanced pancreatic cancer and severe abdominal 
pain with poor response to narcotics. Patient had EUS guided CPN. Celiac axis is localized 
under EUS (left image) and absolute alcohol was then injected to both sides of the celiac axis 
(seen as a white cloud surrounding the aorta in the right image) .  
Pain is reported in the majority of patients with advanced pancreatic cancer (90%), and 
effective pain control can be achieved in 70-90% of these patients with CPN. (Ramesh & 
Varadarajulu, 2008; Puli et al, 2009; Kaufman et al, 2010) This procedure entails the injection 
of absolute alcohol under EUS guidance to destroy the sympathetic plexus near the celiac 
axis. A similar technique involving the injection of triamcinolone is performed in patients 
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with chronic pancreatitis for pain control. (Ramesh & Varadarajulu, 2008) Significant 
reduction of pain scores 12 weeks after CPN was observed in 30 patients with advanced 
intra-abdominal malignancy, while 91% of these patients required same or less pain 
medication and 88% of patients had persistent improvement in their pain score. (Wiersema 
et al, 1996) Similarly, in another study of 58 patients with unresectable pancreatic cancer, 
EUS-guided CPN lowered pain scores in 78% at 2 weeks and a sustained response was 
noted until 24 weeks. (Naresh et al, 2001) The most commonly reported complications after 
CPN are orthostatic hypotension in 10-15% and transient diarrhea in 9%. (Gunaratnam et al, 
2001) Recently, a retrospective analysis to determine predictors of response to CPN in a 
cohort of 64 patients with pancreatic cancer revealed that visualization o the celiac ganglia 
was the best predictor of response: patients with visible ganglia were >15 times more likely 
to respond (p < 0.001). (Ascunce et al, 2011) 
Percutaneous ethanol injection is an effective treatment for cystic and solid lesions in the 
liver. Successful ethanol ablation of cysts in the thyroid, parathyroid, kidneys, and spleen 
have been reported with minimal side effects. EUS offers minimally invasive access to 
perform ablation of pancreatic lesions. This EUS-guided ablative therapy may have 
important clinical applications in the treatment of solid (adenocarcinomas, neuroendocrine 
tumors) and cystic pancreatic lesions (mucinous cystic neoplasm, IPMN), especially in 
nonoperative candidates. A pilot study in porcine models showed that ethanol injection into 
normal porcine pancreas results in focal inflammation, necrosis and fibrosis at the injection 
site. (Aslanian et al, 2005) Another pilot study reported the safety and feasibility in humans, 
after 25 patients underwent ethanol lavage of different cystic pancreatic lesions (mucinous 
cystic neoplasms, IPMNs, serous cystadenomas, and pseudocysts) with no side effects or 
complications reported in short and long-term follow up. (Gan et al, 2005) The approach to 
this technique involves aspirating the cyst content with a 22 gauge needle until collapse is 
achieved. Ethanol is then injected into the cyst, and the cyst is lavaged for 3 to 5 min. The 
cystic lesion is finally drained of fluid at the conclusion of the lavage. (Trevino & 
Varadarajulu, 2011) Studies in animals have revealed that EUS-guided injection of ethanol 
into the pig pancreas results in a localized concentration-depended tissue necrosis without 
complications, with a visible necrotic area of 20.8mm (+/- 4.3mm) after injection of 40% to 
100% ethanol. (Matthes et al, 2007) A small study demonstrated no cyst recurrence by CT 
after a median follow up of 26 months (including suspected mucinous cysts). However, 
longer follow up is still needed before considered these patients cured. (DeWitt et al, 2010) 
The main potential problem of EUS-guided ethanol ablation is the risk of acute pancreatitis 
due to diffusion of alcohol outside the lesion into the main pancreatic duct and/or the 
pancreatic parenchyma. (Giovannini, 2007) 
EUS-guided fine needle injection (FNI) has been proposed as a new technique for delivery 
of anti-tumor agents for patients with locally advanced malignancy. Few small size studies 
(8-37 patients) have been published, reporting the safety and feasibility of direct injection of 
different agents, such as allogenic mixed lymphocyte culture or cytoimplant (cytokine 
production within a tumor may lead to regression by host immune mechanisms, and 
cytoimplants produce such a cytokine response), ONYX-015 (adenovirus that selectively 
replicates and kills malignant cells) and TNFerade [replication-deficient adenovector 
containing the human tumor necrosis factor (TNF)-α gene, regulated by radiation-inducible 
promoter Egr-1]. The commonly reported side effects are low grade fever without 
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leukocytosis, nausea, abdominal pain and elevated liver enzymes and bilirrubin. No 
pancreatitis has been reported, but few cases of sepsis and two cases of duodenal perforation 
occurred prior to the institution of prophylactic antibiotic and due to the rigid endoscope tip 
during transduodenal approach, respectively. These studies revealed partial response or at 
least tumor stabilization. Perhaps combination of systemic chemotherapy and/or radiation 
with EUS-FNI would improve outcomes. This field will continue to expand with the 
refinement of echoendoscopes, delivery systems and novel local antitumor agents. (Trevino 
and Varadarajulu, 2010; Klapman & Chang, 2005; Verna & Dhar, 2008; Chang, 2006)  
Implantation of fiducial markers to facilitate stereotactic radiotherapy and radioactive seeds 
for brachytherapy can be performed under EUS guidance. Fiducials can be placed into 
tumors to enable higher doses of targeted radiotherapy while sparing adjacent healthy 
tissue with low risk of complications. This technique has a reported technical success rate of 
84-94%, and its direct impact on patient management is promising but still under clinical 
investigation. A total of 3-6 gold fiducials are placed within the tumor in different planes 
under EUS guidance. Immediate complications are uncommon and involve needle 
malfunction and minor bleeds with no significant drop in hemoglobin. Although fiducials 
can spontaneously migrate from the initial injection site, the reported rate of migration is 
low (7%), and no migration-related complications have been documented. (Ramesh & 
Varadarajulu, 2008; Park et al, 2010; Sanders et al, 2010) The EUS-guided placement of 
fiducials has traditionally involved the use of 19 gauge needles. However, a recently 
published case series reported the feasibility of using a 22 gauge needle, which may permit 
greater access when compared to a 19 gauge needle technique. (Ammar et al, 2010) 
Brachytherapy is a useful method for local control of malignant tumors, including pancreas. 
After the placement of the radioactive seeds, the tissue is exposed to steady radiation, 
leading to localized ablation and avoiding the radiation of normal tissues surrounding the 
malignant lesion. EUS-guided brachytherapy has been performed to place radioactive 
iodine seeds into the locally advanced pancreatic tumor mass, with significant improvement 
in pain scores and also improvement in performance status scores. When assessing the 
tumor response, an 80% rate of positive response (decrease in tumor size) or stable disease 
has been reported. Hematologic toxicity is usually mild, but includes neutropenia, 
thrombocytopenia, and anemia. Other reported complications reported less frequently are 
pancreatitis and pseudocyst formation. (Sun et al, 2006) Small size studies have 
demonstrated the technical feasibility of EUS-guided implantation of radioactive seeds in 
pancreatic tumors, and the technique appears to be well tolerated. (Ramesh & Varadarajulu, 
2008; Sun et al, 2006) However, larger studies evaluating this technique and its role in a 
multimodality approach in combination with chemotherapy and/ or external beam 
radiation are needed. 
Radiofrequency ablation (RFA) is a well-established procedure that provides palliation for 
various malignant diseases. RFA causes a relatively predictable zone of coagulation necrosis 
by intense tissue heating. Accurate and precise targeting of the tumor is important to 
maximize the yield and minimize the morbidity. (Klapman & Chang, 2005) This technique is 
emerging as one of the safest and most predictable for thermal tumor ablation and is 
traditionally administered with percutaneous or surgical approaches. (Verma & Dhar, 2008) 
The feasibility and effectiveness of EUS-guided RFA has been evaluated in animal models 
and the probe is deployed by a 19 gauge needle inducing coagulative necrosis. (Ramesh & 
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Varadarajulu, 2008) Further application of this technique has been impeded because of the 
lack of a retractable needle electrode array to ablate large areas. This was overcome by the 
development of a retractable umbrella-shaped electrode array that has delivered effective 
coagulation necrosis of large areas in the porcine model. (Varadarajulu et al, 2009)  
 
 
Fig. 7. 66 year-old male with locally advanced, non resectable, pancreatic cancer that 
underwent EUS-guided of fiducials in the pancreatic head for stereotactic radiotherapy. A 
5cm pancreatic head mass was identified by EUS (left image), followed by placement of a 
total of 9 gold fiducials into the inferior and superior aspects of the tumor under 
fluoroscopy (right image) 
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Another experimental technique is photodynamic therapy (PDT), which involves the 
systemic administration of a photosensitizing agent, followed by placement of light-
diffusing photodynamic fibers into the target malignant tissue. This is usually accomplished 
percutaneously, but it has recently been placed endoscopically with EUS guidance in the 
pancreas of porcine models. (Verma & Dhar, 2008) In animal models, the EUS-guided PDT 
of pancreas and other organs has proved to be safe and effective. (Chan et al, 2004) 
These two EUS-guided ablative techniques, RFA and PDT, have only been performed in 
animal models and further studies in the safety and efficacy in humans are needed before 
considering their use in the palliation of advanced pancreatic cancer. 
4. Conclusion 
Endoscopy is a constantly evolving field with a major role in the diagnosis of pancreatic 
cancer as well as palliation of advanced cases. Pancreatic cancer must be managed with a 
multidisciplinary approach. EUS is the most frequently used modality for the diagnosis and 
staging of pancreatic cancer. Treatment with curative intention involves surgery, with the 
use of adjuvant therapy (chemotherapy and/ or radiation) in some cases. Most cases are 
diagnosed when curative resection is not possible and different endoscopic approaches can 
be used in a palliative attempt for symptomatic relieve of pain, jaundice or obstruction.  
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